Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2010 Dec 1;20(23):7159-63. doi: 10.1016/j.bmcl.2010.07.054. Epub 2010 Jul 24.

The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: the second clinical candidate having a shorter and favorable human half-life.

Author information

1
Pfizer Global Research and Development, Chesterfield, MO 63017, USA. jl47wang@yahoo.com

Abstract

In this Letter, we provide the structure-activity relationships, optimization of design, testing criteria, and human half-life data for a series of selective COX-2 inhibitors. During the course of our structure-based drug design efforts, we discovered two distinct binding modes within the COX-2 active site for differently substituted members of this class. The challenge of a undesirably long human half-life for the first clinical candidate 1t(1/2)=360 h was addressed by multiple strategies, leading to the discovery of 29b-(S) (SC-75416) with t(1/2)=34 h.

PMID:
20709553
DOI:
10.1016/j.bmcl.2010.07.054
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center